- To prevent infections after chemotherapy due to decreased white blood cells (neutropenia)
GRAFEEL VIAL
MRP | : |
|
Price | : | ₹280.00 |
You Save | : | ₹444.31 (61.34%) |
1 vial(s) of 1ml
Grafeel 300mcg injection contains filgrastim, a white blood cell growth factor (granulocyte-colony stimulating factor). It is an FDA-approved medication designed to mitigate the risk of febrile neutropenia (fever or infection associated with a low white blood cell count) and to shorten the duration of neutropenia (a low white blood cell count) in individuals undergoing chemotherapy for non-myeloid cancers. This injection is also utilized to boost white blood cell counts and reduce the duration of fever in patients with acute myeloid leukemia.
Furthermore, Grafeel 300mcg injection is beneficial for individuals undergoing bone marrow transplants and those with severe chronic neutropenia (a persistently low number of neutrophils in the blood). It serves to prepare the blood for leukapheresis, a medical procedure involving the removal of specific blood cells. Another significant application is to enhance the survival rate in people exposed to harmful levels of radiation, which can severely damage the bone marrow. Additionally, it is indicated for patients with advanced HIV infection to help reduce their risk of infections.
Belonging to the class of medications known as colony-stimulating factors, Grafeel 300mcg injection works by stimulating the body’s production of white blood cells. White blood cells are crucial for the body’s defense against infections. Since these cells are highly susceptible to the effects of chemotherapy, their numbers can decrease significantly, leaving the body vulnerable to bacterial infections. It is important to inform your physician if you have or have had liver disease, kidney problems, sickle cell anemia, or bone disease. Common side effects associated with this injection include fever, pain, rash, cough, shortness of breath, and nosebleeds.